<DOC>
	<DOCNO>NCT02700529</DOCNO>
	<brief_summary>Leukotriene B4 ( LTB4 ) inhibit lymphangiogenesis mouse tail model lymphedema elevate tissue patient lymphedema . Ubenimex inhibitor leukotriene A4 hydrolase ( LTA4H ) , biosynthetic enzyme LTB4 . This proof-of-concept study design randomize , double-blind , placebo-controlled study compare ubenimex 150 mg , 3 time daily ( total daily dose 450 mg ) placebo 6 month treatment period patient secondary leg lymphedema . The primary objective study : - To evaluate efficacy ubenimex patient secondary leg lymphedema - To evaluate safety tolerability ubenimex patient secondary leg lymphedema</brief_summary>
	<brief_title>Ubenimex Adult Patients With Secondary Lymphedema The Lower Limb ( ULTRA )</brief_title>
	<detailed_description />
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Ubenimex</mesh_term>
	<criteria>1 . Secondary leg lymphedema , base positive lymphoscintigraphy study affect leg . 2 . Swelling least 1 leg completely reverse leg elevation compression . 3 . Stage II great lymphedema , base International Society Lymphology ( ISL ) stag system . 4 . Completion full course complete decongestive therapy ( CDT ) . 5 . Stable limb volume ( within 10 % screening worse/affected leg ) . 6 . Ambulatory status ( use walk aid permit ) . 7 . Presence incite event/risk factor lymphedema , ( limit ) surgery , trauma , radiation therapy . 8 . Agree use medically acceptable method contraception , possibility conception exist . Exclusions Based Lymphedema : 1 . Primary lymphedema , family history , syndrome include lymphedema . 2 . Occurrence lymphedema another body part ( e.g , upper extremity , trunk , head neck , genitalia ) . 3 . Recent initiation , intention initiate CDT maintenance physiotherapy lymphedema . Exclusions Based Other Medical Conditions 4 . Deep venous thrombosis either low limb systemic anticoagulation within 6 month 5 . Other medical condition could lead acute chronic leg edema . 6 . Other medical condition could result symptom overlap lymphedema affect leg . 7 . History clot disorder ( hypercoagulable state ) . 8 . Chronic ( persistent ) infection either low limb . 9 . Cellulitis infection either low limb use antibiotic cellulitis within 3 month prior screen . 10 . Current evidence malignancy . 11 . History malignancy within previous 3 year , except nonmelanoma skin cancer cervical carcinoma situ treat curative intent . 12 . Currently receive chemotherapy radiation therapy . 13 . Life expectancy &lt; 2 year reason . 14 . Pregnancy nursing . 15 . Substance abuse ( alcohol drug abuse ) within 6 month prior screen . Exclusions Based Concurrent Medication Use 16 . Regular concurrent use regular use within 6 month screen another leukotriene pathway inhibitor . 17 . Concurrent antibiotic use . 18 . Concurrent use agent active sphingosine1phosphate ( S1P ) pathway . 19 . Concurrent use unapproved ( include herbal ) treatment lymphedema . Exclusions Based Laboratory Values 20 . Significant chronic renal insufficiency require dialytic support . 21 . Hepatic dysfunction . 22 . Absolute neutrophil count &lt; 1500 mm3 screen . 23 . Hemoglobin concentration &lt; 9 g/dL screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>